Kidney Disease in the United States
- Approximately 20 million Americans have kidney disease.1
- Early kidney disease has no symptoms. If left undetected, it can progress to kidney failure,
which requires dialysis or a transplant, with little or no warning.
- By the end of 2004, more than 136,000 people were living with a kidney transplant, and
almost 335,000 were on dialysis — a number that has nearly tripled since 1988.2
- Public and private spending to treat patients with kidney failure in the United States in 2004
was $32.5 billion.2
- By 2030, more than 2 million people will be receiving treatment for kidney failure.3
Risk Factors
The main risk factors for kidney disease are:
- Diabetes
- High blood pressure
- A family history of kidney failure
- Cardiovascular disease
The most common causes of kidney failure are diabetes and high blood pressure, together accounting for about 69 percent of new cases.2
Detection and Treatment
- Blood and urine tests are the only way to detect kidney disease.
- Kidney disease can be effectively treated if detected early. ACE (angiotensin-converting enzyme) inhibitors4,5,6,7 or
ARBs8,9 (angiotensin receptor blockers) can prevent or slow
progression of kidney disease to kidney failure.
- Intensive management of blood glucose is important for people with diabetes, especially if
they have early stages of kidney disease.10
References
- U.S. Renal Data System (2004). National
Institutes of Health, National Institute of
Diabetes and Digestive and Kidney Diseases,
Bethesda, MD.
- U.S. Renal Data System (2006). National
Institutes of Health, National Institute of
Diabetes and Digestive and Kidney Diseases,
Bethesda, MD.
- Gilbertson D, Solid C, Xue JL, Collins AJ.
Projecting the U.S. ESRD population to 2030.
Presented at 2003 ASN Annual Meeting.
Available at: www.usrds.org/2003/pres/
html/5U_ASN_projections_files/frame.htm.
Posted November 2003. Accessed April 3, 2006.
- Giatras I, Lau J, Levey AS, Angiotensin-Converting-Enzyme Inhibition and Progressive
Renal Disease Study Group. Effect of
angiotensin-converting enzyme inhibitors
on the progression of nondiabetic renal
disease: a meta-analysis of randomized
trials. Annals of Internal Medicine.
1997;127(5):337-345.
- Jafar TH, Schmid CH, Landa M, Giatras I, Toto R,
Remuzzi G, Maschio G, Brenner BM, Kamper A,
Zucchelli P, Becker G, Himmelmann A,
Bannister K, Landais P, Shahinfar S, de Jong PE,
de Zeeuw D, Lau J, Levey AS. Angiotensin-converting
enzyme inhibitors and progression
of nondiabetic renal disease: a meta-analysis
of patient-level data. Annals of Internal
Medicine. 2001;135(2):73-87.
- Kshirsagar AV, Joy MS, Hogan SL, Falk RJ,
Colindres RE. Effect of ACE inhibitors in
diabetic and nondiabetic chronic renal disease:
a systematic overview of randomized placebo-controlled
trials. American Journal of Kidney
Diseases. 2000;35(4):695-707.
- Wright JT Jr, Bakris G, Greene T, Agodoa LY,
Appel LJ, Charleston J, Cheek D, Douglas-
Baltimore JG, Gassman J, Glassock R, Hebert
L, Jamerson K, Lewis J, Phillips RA, Toto RD,
Middleton JP, Rostand SG, African American
Study of Kidney Disease and Hypertension
Study Group. Effect of blood pressure
lowering and antihypertensive drug class on
progression of hypertensive kidney disease:
results from the AASK trial. JAMA.
2002;288(19):2421-2431.
- Lewis EJ, Hunsicker LG, Clarke WR, Berl T,
Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R,
Raz I. Renoprotective effect of the angiotensin-receptor
antagonist irbesartan in patients
with nephropathy due to type 2 diabetes.
New England Journal of Medicine.
2001;345(12):851-860.
- Brenner BM, Cooper ME, de Zeeuw D, Keane
WF, Mitch WE, Parving HH, Remuzzi G,
Snapinn SM, Zhang Z, Shahinfar S, RENAAL
Study Investigators. Effects of losartan on
renal and cardiovascular outcomes in patients
with type 2 diabetes and nephropathy.
New England Journal of Medicine.
2001;345(12):861-869.
- National Kidney and Urologic Diseases
Information Clearinghouse. Kidney Disease
of Diabetes. Washington, DC: US Government
Printing Office; 2006. NIH Publication 06-3925.
Fact sheet.
|